



F-star Presents Preclinical Data at AACR 2017 on Tumour Growth Inhibition in Colon Carcinoma Models using Bispecific Antibodies

F-star's bispecific mAb² shows increased anti-tumour activity compared to antibodies given in combination

Cambridge, UK – 05 April 2017 – F-star, a biopharmaceutical company developing novel bispecific antibodies with a focus on immuno-oncology, today presents preclinical data on its LAG-3/PD-L1 bispecific programme at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, D.C. This data provides insights into the clinical potential of F-star's proprietary Modular Antibody Technology™. The poster titled "*A LAG-3/PD-L1 bispecific antibody inhibits tumour growth in two syngeneic colon carcinoma models*" is available [here](#).

Combining immunotherapeutic antibodies in cancer treatment has shown benefits over single agents. An alternative to combining two antibodies is the development of bispecific antibodies that not only bring two biologies together but may result in novel mechanisms of action that are impossible to attain with combinations.

Using its plug-and-play approach, F-star engineered a bispecific antibody (mAb²™) binding both Lymphocyte-Activation Gene 3 (LAG-3) and Programmed Death-Ligand 1 (PD-L1), two immune check point receptors strongly implicated in allowing cancers to escape immune surveillance.

The results presented at the AACR meeting describe not only that the murine LAG-3/PD-L1 mAb² potentially activates T cells *in vitro*, but also decreases *in vivo* tumour burden in two murine syngeneic tumour models. The study also shows an increased anti-tumour activity with the bispecific as compared to the individual anti-LAG-3 and PD-L1 antibodies given in combination.

Thus, this data supports the preclinical development of FS118, F-star's anti-human LAG-3/PD-L1 mAb² for the treatment of cancer patients.

Session Category:	Clinical Research
Session Title:	Innate Immunity to Generate Adaptive Immunity
Session Date and Time:	Wednesday Apr 5, 2017 8:00 AM - 12:00 PM
Location:	Convention Center, Halls A-C, Poster Section 28
Poster Board Number:	5
Permanent Number:	5651

-Ends-

For further information, please contact:

F-star

John Haurum
Chief Executive Officer
+44 (0)7881 244 040
john.haurum@f-star.com

Jane Dancer
Chief Business Officer
+44 (0)7739 174 297
jane.dancer@f-star.com

Instinctif Partners

Sue Charles/Daniel Gooch
+44 (0)20 7866 7905
F-star@instinctif.com

About F-star

F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. Through the application of its highly efficient Modular Antibody Technology™ platform, F-star is the only biotechnology company able to rapidly create bispecific antibodies with properties virtually identical to a typical antibody. This offers unprecedented ease in the discovery, development, and manufacturing of bispecific antibody products. F-star has currently one programme in the clinic with a second immuno-oncology programme heading toward IND. The Company has built a comprehensive IP estate around its technology and product pipeline, with over 50 patent applications filed and over 25 granted patents.

F-star's management team has a well-established track record in building successful biotech companies, and developing biologics. The team is advised by a world-leading scientific advisory board and a highly experienced board of directors. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including AbbVie, Bristol-Myers Squibb, Merck KgaA and Denali Therapeutics. F-star has raised close to \$100M in non-dilutive capital and revenues. The company currently employs over 80 people at its research site in Cambridge, UK.

For more information visit www.f-star.com